ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells

Leukemia and Lymphoma

Volumn 56, Issue 7, 2015, Pages 2146-2152

  Johnson Farley, Nadine ^a   Veliz, Jonny ^a   Bhagavathi, S ^a   Bertino, Joseph R ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Cell lines and animal models; Chemotherapeutic approaches; Lymphoma and Hodgkin disease

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BORTEZOMIB; CYTARABINE; DOXORUBICIN; METHOTREXATE; PROTEIN BCL 2; PROTEIN BCL XL; RITUXIMAB; SEPANTRONIUM BROMIDE; TEMSIROLIMUS; VENETOCLAX; VINCRISTINE; (+)-JQ1 COMPOUND; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; BAX PROTEIN (53-86); FUSED HETEROCYCLIC RINGS; ONCOPROTEIN; PEPTIDE FRAGMENT; SULFONAMIDE; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOUBLE HIT LYMPHOMA; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IC50; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; BIOMIMETICS; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZEPINES; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOMIMETICS; BLOTTING, WESTERN; BORTEZOMIB; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; LYMPHOMA; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TRIAZOLES; TUMOR CELLS, CULTURED;

EID: 84930379505     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.981172     Document Type: Article

References (23)

1. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
2. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488-496.
3. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202-208.
4. Davids MS, Seymour JF, Gerecitano JF, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. Haematologica 2014;99(Suppl. 1): Abstract 525.
5. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009. Available from: seer. cancer. gov
6. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011;117:2319-2331.
7. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012;25: 145-156.
8. Xu X, Zhang L, Wang Y, et al. Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquistion of MYC: report of two cases and literature review. Int J Clin Exp Pathol 2013;6: 788-794.
9. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11:1149-1159.
10. Turakhia SK, Hill BT, Dufresne SD, et al. Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics. Am J Clin Pathol 2014; 142:339-346.
11. Pan P, Debos L, Benito JM, et al. BCL-2 selective BH3 mimetic ABT-199 is a potent agent for acute myeloid leukemia. Blood 2013; 122(Suppl. 1):Abstract 1456.
12. Th'ng KH, Garewal G, Kearney L, et al. Establishment and characterization of three new malignant lymphoid cell lines. Int J Cancer 1987;39:89-93.
13. Chang H, Messner HA, Wang XH, et al. A human lymphoma cell line with multiple immunoglobulin rearrangements. J Clin Invest 1992;89:1014-1020.
14. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70 : 440-446.
15. Bijnsdorp IV Giovannetti E, Peters GJ. Analysis of drug interactions. Methods Mol Biol 2011;731:421-434.
16. Premkumar DR, Jane EP, Foster KA, et al. Survivin inhibitor YM-155 sensitizes tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. J Pharmacol Exp Ther 2013;346:201-210.
17. KitaA, NakaharaT, YamanakaK, et al. Antitumor effectsofYM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res 2011;35:787-792.
18. Jane EP, Premkumar DR, DiDomenico JD, et al. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther 2013;12:326-338.
19. Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013;121 : 2285-2288.
20. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular Subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-6075.
21. Cheson BD, Bartlett NL, Vose JM, et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma Cancer 2012;118:3128-3134.
22. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146: 904-917.
23. Ott CJ, Kopp N, Bird L et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012;120:2843-2852.